Cargando…

Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia

BACKGROUND: Anti-GD2 antibody is a proven therapy for GD2-postive neuroblastoma. Monoclonal antibodies against GD2, such as chimeric mAb ch14.18, have become benchmarks for neuroblastoma therapies. Pain, however, can limit immunotherapy with anti-GD2 therapeutic antibodies like ch14.18. This adverse...

Descripción completa

Detalles Bibliográficos
Autores principales:	Terme, Mickaël, Dorvillius, Mylène, Cochonneau, Denis, Chaumette, Tanguy, Xiao, Wenhua, Diccianni, Mitchell B., Barbet, Jacques, Yu, Alice L., Paris, François, Sorkin, Linda S., Birklé, Stéphane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3919714/ https://www.ncbi.nlm.nih.gov/pubmed/24520328 http://dx.doi.org/10.1371/journal.pone.0087210

Ejemplares similares

Targeting and killing glioblastoma with monoclonal antibody to O-acetyl GD2 ganglioside
por: Fleurence, Julien, et al.
Publicado: (2016)

A Monoclonal Antibody to O-Acetyl-GD2 Ganglioside and Not to GD2 Shows Potent Anti-Tumor Activity without Peripheral Nervous System Cross-Reactivity
por: Alvarez-Rueda, Nidia, et al.
Publicado: (2011)

Correction: Chimeric Antibody c.8B6 to O-Acetyl-GD2 Mediates the Same Efficient Anti-Neuroblastoma Effects as Therapeutic ch14.18 Antibody to GD2 without Antibody Induced Allodynia
Publicado: (2014)

Anti-GD2 induced allodynia in rats can be reduced by pretreatment with DFMO
por: Diccianni, Mitchell B., et al.
Publicado: (2020)

Long-term continuous infusion of anti-GD2 antibody CH14.18/CHO in relapsed/refractory neuroblastoma patients
por: Lode, Holger, et al.
Publicado: (2013)

Functional Bioassays for Immune Monitoring of High-Risk Neuroblastoma Patients Treated with ch14.18/CHO Anti-GD(2) Antibody
por: Siebert, Nikolai, et al.
Publicado: (2014)

Targeting GD2 after allogeneic SCT: effector cell composition defines the optimal use of ch14.18 and the bispecific antibody construct NG-CU (GD2-CD3)
por: Arendt, A.-M., et al.
Publicado: (2023)

Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy
por: Fleurence, Julien, et al.
Publicado: (2017)

Anti-Gb3 Monoclonal Antibody Inhibits Angiogenesis and Tumor Development
por: Desselle, Ariane, et al.
Publicado: (2012)

Tolerability, response and outcome of high-risk neuroblastoma patients treated with long-term infusion of anti-GD(2) antibody ch14.18/CHO
por: Mueller, Ina, et al.
Publicado: (2017)

Effective combination treatment of GD2-expressing neuroblastoma and Ewing's sarcoma using anti-GD2 ch14.18/CHO antibody with Vγ9Vδ2+ γδT cells
por: Fisher, Jonathan P H, et al.
Publicado: (2015)

Reduction of CD11b(+) myeloid suppressive cells augments anti-neuroblastoma immune response induced by the anti-GD(2) antibody ch14.18/CHO
por: Siebert, Nikolai, et al.
Publicado: (2020)

Immunomonitoring of Stage IV Relapsed Neuroblastoma Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplantation and Subsequent GD2 (ch14.18/CHO) Antibody Treatment
por: Seitz, Christian Martin, et al.
Publicado: (2021)

Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2
por: Hoseini, Sayed Shahabuddin, et al.
Publicado: (2017)

Biology of GD2 ganglioside: implications for cancer immunotherapy
por: Machy, Pierre, et al.
Publicado: (2023)

TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy
por: McNerney, KO, et al.
Publicado: (2022)

A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors
por: Bishop, Michael W., et al.
Publicado: (2020)

Therapeutic efficacy of antibody-drug conjugates targeting GD2-positive tumors
por: Kalinovsky, Daniel V, et al.
Publicado: (2022)

Generation and Characterization of a Human/Mouse Chimeric GD(2)-Mimicking Anti-Idiotype Antibody Ganglidiximab for Active Immunotherapy against Neuroblastoma
por: Eger, Christin, et al.
Publicado: (2016)

Anti-GD2 antibody dinutuximab inhibits triple-negative breast tumor growth by targeting GD2(+) breast cancer stem-like cells
por: Ly, Stanley, et al.
Publicado: (2021)

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells
por: Yankelevich, Maxim, et al.
Publicado: (2023)

GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
por: Park, Jeong A., et al.
Publicado: (2020)

IgA antibody immunotherapy targeting GD2 is effective in preclinical neuroblastoma models
por: Stip, Marjolein C, et al.
Publicado: (2023)

Inhibition of tumor angiogenesis by globotriaosylceramide immunotargeting
por: Birklé, Stéphane, et al.
Publicado: (2013)

Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
por: Simon, Thorsten, et al.
Publicado: (2011)

GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody
Publicado: (1982)

In silico Driven Redesign of a Clinically Relevant Antibody for the Treatment of GD2 Positive Tumors
por: Ahmed, Mahiuddin, et al.
Publicado: (2013)

Antitumor activity of an immunocytokine composed of an anti-GD2 antibody and the IL-15 superagonist RLI
por: Vincent, Marie, et al.
Publicado: (2013)

Translational immunoPET imaging using a radiolabeled GD2-specific antibody in neuroblastoma
por: Schmitt, Julia, et al.
Publicado: (2022)

Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
por: Larrosa, Cristina, et al.
Publicado: (2023)

A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
por: Ozkaynak, M. Fevzi, et al.
Publicado: (2018)

Self-patterning Gd nano-fibers in Mg-Gd alloys
por: Li, Yangxin, et al.
Publicado: (2016)

Structure Based Refinement of a Humanized Monoclonal Antibody That Targets Tumor Antigen Disialoganglioside GD2
por: Ahmed, Mahiuddin, et al.
Publicado: (2014)

Preparation and Evaluation of the Fully Humanized Monoclonal Antibody GD-mAb Against Respiratory Syncytial Virus
por: Tian, Puyuan, et al.
Publicado: (2019)

Multimerization through Pegylation Improves Pharmacokinetic Properties of scFv Fragments of GD2-Specific Antibodies
por: V. Kholodenko, Irina, et al.
Publicado: (2019)

Anti-GD2 antibody and Vorinostat immunocombination therapy is highly effective in an aggressive orthotopic neuroblastoma model
por: van den Bijgaart, Renske J. E., et al.
Publicado: (2020)

Corrigendum: A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children’s Oncology Group Study ANBL0931
por: Ozkaynak, M. Fevzi, et al.
Publicado: (2018)

Digital TDPAC with rare earth isotope $^{169}$Yb, $^{147}$Gd, and $^{149}$Gd in Yb and Gd Doped CeO$_{2}$ and $^{147}$Gd in GdBa$_{2}$ Cu$_{3}$ O$_{7−\delta}$
por: Roeder, Jens, et al.
Publicado: (2011)

Anti-GD2-ch14.18/CHO coated nanoparticles mediate glioblastoma (GBM)-specific delivery of the aromatase inhibitor, Letrozole, reducing proliferation, migration and chemoresistance in patient-derived GBM tumor cells
por: Tivnan, Amanda, et al.
Publicado: (2017)

Miller-Fisher syndrome with positive anti-GD1b and anti-GM1 antibodies combined with multiple autoimmune antibodies: A case report
por: Zhang, Limei, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0gqkdlgkejtnqs3p8h6tn6i1eq